Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine

[1]  J. Shiver,et al.  Vectored Gag and Env but Not Tat Show Efficacy against Simian-Human Immunodeficiency Virus 89.6P Challenge in Mamu-A*01-Negative Rhesus Monkeys , 2005, Journal of Virology.

[2]  Eddy Pasquier,et al.  The Glutamine-rich Region of the HIV-1 Tat Protein Is Involved in T-cell Apoptosis* , 2004, Journal of Biological Chemistry.

[3]  J. Heeney,et al.  Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. , 2004, Vaccine.

[4]  P. Kaleebu,et al.  Full-length HIV-1 Tat protein necessary for a vaccine. , 2004, Vaccine.

[5]  J. Lebreton.  A Possible Improvement for Structure‐Based Drug Design Illustrated by the Discovery of a Tat HIV‐1 Inhibitor. , 2004 .

[6]  J. Tappero,et al.  Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX®B/E HIV vaccine trial, Bangkok, Thailand , 2004, AIDS.

[7]  A. Romieu,et al.  Specificity and effect on apoptosis of Tat antibodies from vaccinated and SHIV-infected rhesus macaques and HIV-infected individuals. , 2003, Vaccine.

[8]  Qiang Zhou,et al.  HIV‐1 Tat targets microtubules to induce apoptosis, a process promoted by the pro‐apoptotic Bcl‐2 relative Bim , 2002, The EMBO journal.

[9]  E. Bouveret,et al.  Tat HIV-1 Primary and Tertiary Structures Critical to Immune Response Against Non-homologous Variants* , 2002, The Journal of Biological Chemistry.

[10]  G. Sutter,et al.  Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08. , 2002, DNA and cell biology.

[11]  A. Osterhaus,et al.  Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. , 2002, Vaccine.

[12]  R. Kaul,et al.  HIV-1 and AIDS: what are protective immune responses? , 2002, Journal of HIV therapy.

[13]  Mark G. Lewis,et al.  Outcome of Simian-Human Immunodeficiency Virus Strain 89.6p Challenge following Vaccination of Rhesus Macaques with Human Immunodeficiency Virus Tat Protein , 2002, Journal of Virology.

[14]  Todd M. Allen,et al.  Tat-Vaccinated Macaques Do Not Control Simian Immunodeficiency Virus SIVmac239 Replication , 2002, Journal of Virology.

[15]  John P. Moore,et al.  AIDS vaccine models: Challenging challenge viruses , 2002, Nature Medicine.

[16]  Neff Walker,et al.  Estimated Global Distribution and Regional Spread of HIV‐1 Genetic Subtypes in the Year 2000 , 2002, Journal of acquired immune deficiency syndromes.

[17]  B. Ensoli,et al.  HIV-1 Tat vaccines. , 2001, Virus research.

[18]  R. Kaul,et al.  How important is the 'quality' of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection? , 2001, Immunology letters.

[19]  Yuntao Wu,et al.  Selective Transcription and Modulation of Resting T Cell Activity by Preintegrated HIV DNA , 2001, Science.

[20]  M. Re,et al.  Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. , 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[21]  E. Rosenberg,et al.  The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  C. Pannecouque,et al.  1H-13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein. , 2000, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[23]  J. Estaquier,et al.  Early changes in peripheral blood T cells during primary infection of rhesus macaques with a pathogenic SIV , 2000, Journal of medical primatology.

[24]  T. Lehner,et al.  Generation of CD8+ T cell-generated suppressor factor and beta-chemokines by targeted iliac lymph node immunization in rhesus monkeys challenged with SHIV-89.6P by the rectal route. , 2000, AIDS research and human retroviruses.

[25]  K. Jeang,et al.  Multifaceted Activities of the HIV-1 Transactivator of Transcription, Tat* , 1999, The Journal of Biological Chemistry.

[26]  Y. Cao,et al.  Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Gallo.  Tat as one key to HIV-induced immune pathogenesis and Pat toxoid as an important component of a vaccine , 1999 .

[28]  J. Heeney,et al.  Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine , 1999, Nature Medicine.

[29]  D. Olive,et al.  Full Peptide Synthesis, Purification, and Characterization of Six Tat Variants , 1999, The Journal of Biological Chemistry.

[30]  Gupta,et al.  Aluminum compounds as vaccine adjuvants. , 1998, Advanced drug delivery reviews.

[31]  W. Blattner,et al.  Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. , 1998, Journal of human virology.

[32]  H. Fleury,et al.  Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals , 1997, Journal of virology.

[33]  N. Haigwood,et al.  Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival , 1997, Journal of virology.

[34]  P. Alzari,et al.  cDNA Cloning and Sequencing Reveal the Major Horse Allergen Equ c1 to Be a Glycoprotein Member of the Lipocalin Superfamily* , 1996, The Journal of Biological Chemistry.

[35]  E. Loret,et al.  Conformational Heterogeneity in Two Regions of TAT Results in Structural Variations of This Protein as a Function of HIV-1 Isolates* , 1996, The Journal of Biological Chemistry.

[36]  V. Metelev,et al.  Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. , 1995, Science.

[37]  P. S. Ho,et al.  Circular dichroism and molecular modeling yield a structure for the complex of human immunodeficiency virus type 1 trans-activation response RNA and the binding region of Tat, the trans-acting transcriptional activator. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Spouge.  Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[39]  B. Berkhout,et al.  TAR-independent activation of the HIV-1 LTR: Evidence that Tat requires specific regions of the promoter , 1990, Cell.

[40]  S. Salahuddin,et al.  Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients , 1990, Nature.

[41]  F. Brun-Vézinet,et al.  A highly defective HIV-1 strain isolated from a healthy Gabonese individual presenting an atypical western blot. , 1989, AIDS.

[42]  C. Pannecouque,et al.  Discovery of a Tat HIV-1 Inhibitor through Computer-Aided Drug Design , 2003 .

[43]  S. Opi,et al.  Homonuclear (1)H-NMR assignment and structural characterization of human immunodeficiency virus type 1 Tat Mal protein. , 2001, Biopolymers.

[44]  A. Burny,et al.  Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Gallo.  Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Gonda,et al.  The trans-activator gene of HTLV-III is essential for virus replication , 1986, Nature.

[47]  A. Geretti,et al.  Uva-dare (digital Academic Repository) Human Immunodeficiency Virus Type 1 Rev-and Tat-specific Cytotoxic T Lymphocyte Frequencies Inversely Correlate with Rapid Progression to Aids , 2022 .